Название продукции:9-Bromo-5,6-dihydro-2-iodo-imidazo[1,2-d][1,4]benzoxazepine

IUPAC Name:12-bromo-4-iodo-9-oxa-3,6-diazatricyclo[8.4.0.0²,⁶]tetradeca-1(14),2,4,10,12-pentaene

CAS:1282516-69-1
Молекулярная формула:C11H8BrIN2O
Чистота:95%+
Номер в каталоге:CM152652
Молекулярная масса:391.01

Упаковочная единица Доступно для заказа Цена ($) Количество
CM152652-100mg in stock ŸȅŸ
CM152652-250mg in stock ƚdžƚ
CM152652-10g in stock ƚȖŞȅ
CM152652-25g in stock ȅƚƴȖ
CM152652-100g in stock ŸƐƴŞdž

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:1282516-69-1
Молекулярная формула:C11H8BrIN2O
Точка плавления:-
Smiles-код:IC1=CN2CCOC3=CC(Br)=CC=C3C2=N1
Плотность:
Номер в каталоге:CM152652
Молекулярная масса:391.01
Точка кипения:
Номер Mdl:MFCD22690733
Хранение:2-8°C

Category Infos

Imidazoles
Imidazole is an important five-membered nitrogen-containing heterocyclic compound. Among the numerous heterocyclic compounds, imidazole and its derivatives are regarded as a unique and multifaceted scaffold material due to their diverse applications in industrial, organic and pharmaceutical chemistry. Imidazoles interact in different ways with many therapeutic targets, enzymes and receptors in biological systems and thus exhibit a wide range of biological activities. In particular, several imidazoles can be used as clinical drugs to treat various types of cancer with high therapeutic efficacy. Furthermore, imidazoles are one of the most critical segments in the field of anti-covid-19 virus drug discovery due to their ability to interact with active targets in living systems.
Imidazole Manufacturer
As a professional imidazole manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

Column Infos

Inavolisib
Genentech’s Phase III results show that the Inavolisib (GDC-0077) treatment meets the primary end point in hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated Breast Cancer. The combination of Inavolisib with Palbociclib and fulvestrant improves the progression-free survival (PFS) in the first line. Inavolisib is a potent selective inhibitor of PI3K alpha (PI3Kα) that binds to the ATP-binding site of p110α, and promotes the degradation of mutated p110α.